Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a U.S public company that is developing a platform that leverages novel drug-screening tools to create cannabinoid-based therapies for cancer that are more precise to a patient’s profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer.
Cannabinoids & Cancer:
Cancer patients worldwide require clarity and transparency into and during their cannabinoid-based treatment to optimize therapeutic results. Cannabis Pharmaceuticals advances cannabinoid based therapies by providing precise data pertaining to the patient’s cancer cells response to a plethora of cannabinoid compositions.
Core member of Cannabics’s founding team. Prior to becoming CEO at Cannabics, Mr. Barad spent years in the online media world, taking part in many different ventures and businesses. Alongside serving as the CEO of a digital media company for over 13 years, Mr. Barad also participated in other business collaborations in many different areas including, but not limited to, the development and use of big-data and Artificial Intelligence to develop predictive models for decision making processes. Eyal has a BA in Economics & International Relations from the Hebrew University in Jerusalem and an MBA with Honors from Haifa University.
Mr. Yariv, 42, brings over 20 years of successful executive experience in the medical industry. Mr. Yariv was part of the founding group of BreathID, an Oridion Medical (now medtronic) business unit and its subsequent spinoff company BreathID Inc., (now Exalenz Bioscience), which develops and manufactures advanced non-invasive diagnostic medical devices for gastrointestinal and liver conditions. Mr. Yariv also co-founded SimuTec, a medical simulation and training company in Brazil that develops and commercializes advanced personalized Virtual Reality training programs for physicians.
An environmentalist with vast experience as an entrepreneur in the medical cannabis field, with broad experience in management and finance in medical cannabis companies that operate in regulated markets. Mr. Borochov was the original Founder of Cannabics Pharmaceuticals Inc.
Dr. Ballan holds a Ph.D. in Neurophysiology, Brain Waves and Cortical Connectivity in Attention. After obtaining his Ph.D. he was an entrepreneur in the field of neurofeedback and developed “Luna Mind” – recreational brain-computer interfaces. Dr. Ballan holds an M.Sc. from Tel-Aviv University – Magna Cum Laude – in molecular biology and anticancer drug development. Dr. Ballan was part of the research team which developed Salirasib (Treatment for Non-Small Cell Lung Cancer). Since 2005 Eyal has been teaching the “Second Attention”- Neuro-Physiological aspects of Higher Perception and Cognition.
Has over 20 years of broad experience in corporate finance, accounting, M&A transactions, IPO’s and operations. Mr. Ben-Or is CEO & Founder of one of the few financial firms in Israel to have the International Standard on Assurance Engagement (ISAE 3402/SAS 70 Type II) assurance with control compliances, the new global standard for assurance reporting. He previously served as an Auditor at PricewaterhouseCoopers Accounting Firm. Mr. Ben-Or holds a BA degree in Business from the College of Administration, an MBA degree from the Bar Ilan University and is a Certified Public Accountant.
With extensive experience in both medical cannabis and digital media, Mr. Permont served as founding team member, communications director and patient instructor at Israel's first and largest medical cannabis grower for a period of 7 years, while serving as VP of Business Development for 11 years in a digital media company. Mr. Permont currently serves as the company's Vice President of Investor Relations and Public Relations.
Dr. Hochman holds a Ph.D. in Cancer Immunology. He brings more than 20 years of experience in versatile R&D leadership and management positions in innovative biotechnology and startup companies. Before joining cannabics, Dr. Hochman was a Co-Founder and VP R&D at SURI Technologies, a company focusing on developing personalized cancer immunotherapy. Previously he was the founder of Biology Research Services, a company that provided tailor-made solutions for startups research, and managed the Bioassay and HTS units at QBI and Rosetta Genomics.
Took the company public on the US exchange and is a native Washingtonian. David brings a dynamic and varied background, having worked in the Diplomatic Corps in the Israeli Foreign Office as well as a Congressional Aide in the US Congress, and General Counsel to consultants at the World Bank as well as the IDB, EX-IM and IMF in Washington, DC. He has a BA in International Relations from the University of Maryland, and JD from Antioch DC School of Law.
Head of Advisory Board and Business Development Advisor Dr. Feiler is a banker and hedge fund manager. Dr. Feiler served as Board Member of Advanced Vision Technology, traded on the Frankfurt Stock Exchange (VSJ), served on the Board of Safra Bank Mutual Fund Division; and has served as Administrative advisor for the Government of Ras Al Khaimah, UAE. Dr. Feiler has published extensively on business opportunities and strategies and was a frequent speaker in world events including the World Economic Forum in Davos
Dr. Mofkadi holds a Ph.D in Financial Economics from Tel Aviv University. He is a lecturer at Tel Aviv University, the Interdisciplinary Center in Herzliya and universities abroad. He is the author of ‘The Handbook of Corporate Valuation’. Dr. Mofkadi provides expert opinions in financing, economic, and legal proceedings, writing valuations and optimal pricing policies as well as economic analysis of competition and regulatory aspects, risk assessment and more.
Prof. Amos Toren is the Director of Pediatric Hemato-Oncology and BMT Department at the Sheba Medical Center since 2001 and a Professor in the division of Hematology, Sackler School of Medicine Tel-Aviv University. Prof. Toren is a specialist in Pediatrics, General Hematology and Pediatric Hemato-Oncology. He also has a PhD degree in genetics and qualified as a Master of Health Administration (MHA) at the Recannati Business School, Tel-Aviv University. Professor Toren runs numerous clinical studies, investigator initiated, company initiated, unicenter as well as multicenter.
17 years experience in the pharmaceutical industry.
During this time, she has managed pharmaceutical and chemical plants at Taro pharmaceutical industries Ltd as Operation Group Vice president and in Teva Pharmaceutical industries Ltd as Kfar-Saba OSD plant manager. Dr. Ariely-Portnoy managed Teva's largest plant worldwide (9 billion tablets per annum and more than $2B revenues). During her career, she led more than 50 inspections by the US FDA, EMEA, Israeli MOH, and others. Dr. Ariely-Portnoy spearheaded the construction of a 200,000 sq ft pharmaceutical plant, several chemical plants and bio-warehouses, as well as many significant plant expansions for manufacturers of semisolids, liquids and oral solid dosage forms. Between the years 2003-2006, Dr. Ariely-Portnoy was the president of the Israel chapter of the PDA (Parenteral Drug Association). For the last 5 years, Dr. Ariely-Portnoy manages Gsap, a company which consults pharmaceutical, medical device and biotechnology companies in several major fields, including innovative product development, regulation, establishing quality systems and validation services. Dr. Ariely-Portnoy received her B.Sc., M.Sc., and D.Sc. from the Technion Institute of Technology in Haifa, Israel, in the fields of Chemical Engineering and Biomedical Engineering.